Insight Molecular Diagnostics (IMDX) Other Operating Expenses (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Other Operating Expenses data on file, last reported at -$3.5 million in Q1 2026.

• Quarterly Other Operating Expenses fell 268.63% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.3 million (down 46.1% YoY) and the FY2025 annual result came in at $26.9 million, down 35.58% from the prior year.
• Other Operating Expenses retreated to -$3.5 million in Q1 2026 per IMDX's latest filing, from $15.8 million in the prior quarter.
• The five-year high for Other Operating Expenses was $29.4 million in Q4 2024, with the low at -$11.4 million in Q1 2023.
• Average Other Operating Expenses over 5 years is $3.5 million, with a median of $2.6 million recorded in 2023.
• Year-over-year, Other Operating Expenses slumped 330.56% in 2022 and jumped 2495.51% in 2025.
• Insight Molecular Diagnostics' Other Operating Expenses stood at $5.2 million in 2022, then jumped by 128.14% to $11.8 million in 2023, then surged by 149.99% to $29.4 million in 2024, then tumbled by 46.35% to $15.8 million in 2025, then plunged by 122.29% to -$3.5 million in 2026.
• Business Quant data shows IMDX's Other Operating Expenses at -$3.5 million in Q1 2026, $15.8 million in Q4 2025, and $4.8 million in Q3 2025.